AR066170A1 - Anti integrina alfa 5 beta 1 - Google Patents
Anti integrina alfa 5 beta 1Info
- Publication number
- AR066170A1 AR066170A1 ARP080104170A ARP080104170A AR066170A1 AR 066170 A1 AR066170 A1 AR 066170A1 AR P080104170 A ARP080104170 A AR P080104170A AR P080104170 A ARP080104170 A AR P080104170A AR 066170 A1 AR066170 A1 AR 066170A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence
- amino acid
- acid sequence
- identifier
- sequence identifier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere al uso de antagonistas del factor de crecimiento celular endotelial vascular (VEGF) y un anticuerpo alfa5beta1 para el tratamiento del cáncer y la inhibicion de la angiogénesis y/o la permeabilidad vascular, incluso, en la angiogénesis anormal en enfermedades. La presente también se relaciona con las composiciones y kits que comprenden los anticuerpos los anti-alfa5beta1 y los métodos para desarrollarlos o utilizarlos. Reivindicacion 1: Un anticuerpo anti-alfa5beta1 que comprende una secuencia de dominio variable de cadena ligera que comprende (1) un LHVR1 que comprende una secuencia de aminoácidos KASQ-N/S-VGSDVA (identificador de secuencia n°: 10), (2) un LHVR2 que comprende la secuencia de aminoácidos STSYRYS (identificador de secuencia n°: 11) y (3) un LHVR3 que comprende la secuencia de aminoácidos QQY-N/S-SYPFT (identificador de secuencia n°: 12) y una secuencia de dominio variable de cadena pesada que comprende (1) un HHVR1 que comprende la secuencia de aminoácidos GYTF-T/S-DYYLY (identificador de secuencia n°:13), (2) un HHVR2 que comprende la secuencia de aminoácidos GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (identificador de secuencia n°:14) y (3) un HHVR3 que comprende la secuencia de aminoácidos DAYGDWYFDV (identificador de secuencia n°:15).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97547107P | 2007-09-26 | 2007-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066170A1 true AR066170A1 (es) | 2009-07-29 |
Family
ID=40329277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104170A AR066170A1 (es) | 2007-09-26 | 2008-09-25 | Anti integrina alfa 5 beta 1 |
Country Status (22)
Country | Link |
---|---|
US (3) | US7973138B2 (es) |
EP (1) | EP2200700B1 (es) |
JP (1) | JP2011501656A (es) |
KR (1) | KR20100065162A (es) |
CN (1) | CN101888878B (es) |
AR (1) | AR066170A1 (es) |
AU (1) | AU2008304452B2 (es) |
BR (1) | BRPI0816049A2 (es) |
CA (1) | CA2698609A1 (es) |
CL (1) | CL2008002856A1 (es) |
CO (1) | CO6260094A2 (es) |
DK (1) | DK2200700T3 (es) |
HR (1) | HRP20160308T1 (es) |
HU (1) | HUE027911T2 (es) |
MX (1) | MX2010003325A (es) |
MY (1) | MY151191A (es) |
NZ (1) | NZ584838A (es) |
PE (1) | PE20091029A1 (es) |
RU (1) | RU2490277C2 (es) |
SI (1) | SI2200700T1 (es) |
TW (1) | TWI547503B (es) |
WO (1) | WO2009042746A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973138B2 (en) | 2007-09-26 | 2011-07-05 | Genentech, Inc. | Antibodies |
DK2411411T3 (en) | 2009-03-25 | 2016-11-07 | Hoffmann La Roche | New anti-alpha5beta1 antibodies and uses thereof |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
WO2010129904A1 (en) * | 2009-05-08 | 2010-11-11 | Genentech, Inc. | Humanized anti-egfl7 antibodies and methods using same |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
WO2013152011A1 (en) * | 2012-04-02 | 2013-10-10 | Ab Biosciences, Inc. | Novel human control antibodies and uses therefor |
WO2013170168A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla Llc | Multi-specific monoclonal antibodies |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
CN104994874B (zh) | 2012-12-26 | 2017-04-12 | 安科协同公司 | 抗整联蛋白β1抗体组合物及其使用方法 |
CA2898239A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
EP3620468A1 (en) * | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Method for the selection of antibodies against bcma |
ES2720483T3 (es) | 2013-02-28 | 2019-07-22 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti p40 |
EP3052522B1 (en) | 2013-10-03 | 2019-12-11 | Biocare Medical, LLC | Anti-sox10 antibody systems and methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
CN114585416A (zh) * | 2019-04-01 | 2022-06-03 | 莱克制药股份有限公司 | 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN114688461A (zh) * | 2020-12-31 | 2022-07-01 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540933A (en) * | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
PT719859E (pt) | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
CA2319160A1 (en) | 1998-01-23 | 1999-07-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
AU746662B2 (en) | 1998-05-08 | 2002-05-02 | Regents Of The University Of California, The | Methods for detecting and inhibiting angiogenesis |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
MXPA02001439A (es) | 1999-08-11 | 2002-08-30 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis. |
US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
AU2002257004A1 (en) | 2001-02-14 | 2002-10-15 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
EP1517998A2 (en) | 2001-06-18 | 2005-03-30 | EOS Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
JP2005518782A (ja) | 2001-09-17 | 2005-06-30 | プロテイン デザイン ラブス, インコーポレイテッド | ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法 |
US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
WO2004043340A2 (en) | 2002-07-16 | 2004-05-27 | University Of Medicine And Dentistry Of New Jersey | Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
EP1575516B1 (en) * | 2002-11-26 | 2012-05-30 | Abbott Biotherapeutics Corp. | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
WO2004048938A2 (en) | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
WO2004089988A2 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
CA2560508A1 (en) * | 2004-03-24 | 2005-10-06 | Pdl Biopharma, Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
NZ555601A (en) | 2004-12-09 | 2009-07-31 | Centocor Inc | Anti-integrin immunoconjugates, methods and uses |
WO2007060408A2 (en) | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
US20090111828A1 (en) | 2005-11-23 | 2009-04-30 | Astrazeneca Ab | L-alanine derivatives |
US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
ES2544957T3 (es) * | 2006-03-21 | 2015-09-07 | Genentech, Inc. | Terapia combinada que implica antagonistas alfa5beta1 |
BRPI0711796A2 (pt) | 2006-05-24 | 2011-12-06 | Bayer Schering Pharma Aktiendesellschaft | anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida |
US7973138B2 (en) | 2007-09-26 | 2011-07-05 | Genentech, Inc. | Antibodies |
MY150246A (en) | 2008-02-05 | 2013-12-31 | Bristol Myers Squibb Co | Alpha 5 - beta 1 antibodies and their uses |
-
2008
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko active IP Right Grant
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en active Application Filing
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
-
2016
- 2016-03-23 HR HRP20160308TT patent/HRP20160308T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US9284376B2 (en) | 2016-03-15 |
EP2200700A1 (en) | 2010-06-30 |
US20120156129A1 (en) | 2012-06-21 |
RU2490277C2 (ru) | 2013-08-20 |
BRPI0816049A2 (pt) | 2019-09-24 |
HUE027911T2 (en) | 2016-11-28 |
CA2698609A1 (en) | 2009-04-02 |
RU2010116184A (ru) | 2011-11-10 |
SI2200700T1 (sl) | 2016-04-29 |
US20120148572A1 (en) | 2012-06-14 |
MX2010003325A (es) | 2010-04-09 |
AU2008304452B2 (en) | 2014-01-16 |
KR20100065162A (ko) | 2010-06-15 |
CL2008002856A1 (es) | 2009-01-16 |
CN101888878B (zh) | 2014-05-21 |
DK2200700T3 (en) | 2016-04-11 |
PE20091029A1 (es) | 2009-08-19 |
AU2008304452A1 (en) | 2009-04-02 |
NZ584838A (en) | 2012-08-31 |
CO6260094A2 (es) | 2011-03-22 |
TW200924794A (en) | 2009-06-16 |
US7973138B2 (en) | 2011-07-05 |
US8840887B2 (en) | 2014-09-23 |
MY151191A (en) | 2014-04-30 |
EP2200700B1 (en) | 2016-01-13 |
US20090098112A1 (en) | 2009-04-16 |
WO2009042746A1 (en) | 2009-04-02 |
TWI547503B (zh) | 2016-09-01 |
HRP20160308T1 (hr) | 2016-04-22 |
JP2011501656A (ja) | 2011-01-13 |
CN101888878A (zh) | 2010-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066170A1 (es) | Anti integrina alfa 5 beta 1 | |
CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
CL2012000631A1 (es) | Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico. | |
PE20241349A1 (es) | Anticuerpos de union a cd3 | |
AR065496A1 (es) | Anticuerpos anti- il-23 r | |
AR068997A1 (es) | Anticuerpos contra el vegf completamente humano y sus metodos de uso | |
CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
HN2008001104A (es) | Compuestos para anticuerpos de dickpf-1 y70-4 | |
CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
AR060241A1 (es) | Composiciones y metodos de uso para anticuerpos de c-met | |
CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
CL2008003361A1 (es) | Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden. | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
AR077756A1 (es) | Anticuerpos especificos para bacterias gram-positivas | |
ES2674567T3 (es) | Proteínas de fusión biespecíficas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |